ANALYSIS OF SIMULATED CLINICAL TRIALS

ing the kinetics of a given dynamic or functional imaging modality in antiangiogenicstudies. However, these observations will need to be validated prospectively.Clinical Trial Design for Combination Systemic Therapy in HCCAs noted previously, the availability in the clinic of se[r]

(an oral fluoropyrimidine) did not increase efficacy, and in previously untreated pancreatic cancer, bevacizumab did not enhance the efficacy of gemcitabine. Table 80-3 Randomized Phase III Clinical Trials Demonstrating the Efficacy of Bevacizumab in Combination with Chem[r]

Pain self-management support interventions were effective in controlled clinical trials and meta analyses. However, implementation of these complex interventions may not translate into identical effects.

designed, Friedberg et al [7] reported that pharmaceuticalindustry oncology drug company-sponsored trials wereless likely to report unfavorable qualitative conclusionsthan those studies sponsored by non-profit organizations(5% vs. 38%, p = 0.04). Marcia Angell has written exten-sively about t[r]

be clarified in more detail. If we can better understandthe intracellular signalling pathways that are involved incannabinoid antitumour action, determine which inter-cellular factors and processes (for example, angiogenesisand metastasis) are modulated by cannabinoids intumours and which tumours ar[r]

atric Association; 1987. 9. American Psychiatric Association: Diagnostic and Statistical Manual ofMental Disorders (DSM-IV) Washington, DC, USA: American Psychiat-ric Association; 1994. 10. Cantillon M, Daley M: Further superiority of SNRI venlafaxineover SSRI fluoxetine in major depression a[r]

Although the benefit of first-line epidermal growth factor receptor (EGFR) tyrosine-kinase inhibitors (TKIs) over chemotherapy has been demonstrated in several clinical trials, data from clinical practice is lacking and the optimal EGFR TKI to be used remains unclear.

underway, but these require repeated intravitreal injection of the siRNAs; an AAV vector–mediated approach might allow long-term knockdown of VEGF. Gene Therapy for Cancer The majority of clinical gene transfer experience has been in subjects with cancer (Fig. 65-1). As a[r]

In this study, reaction rates of the thermal decomposition reaction of 13 kinds of nitrates, which are main constituents of simulated HLLW (sHLLW), were investigated using thermogravimetrical instrument in a range of room temperature to 1000 °C.

Gupta S, Wistuba II: Decitabine effect on tumor global DNA methylationand other parameters in a phase I trial in refractory solid tumors andlymphomas. Clin Cancer Res 2009, 15(11):3881-3888.46. Melenhorst JJ, Scheinberg P, Chattopadhyay PK, Gostick E, Ladell K,Roederer M, Hensel NF, Douek DC, Barret[r]

with HCC. The success of living related donor liver transplantation programs has also led to patients receiving transplantation earlier for HCC and often with greater than minimal tumors. Adjuvant Therapy The role of adjuvant chemotherapy for patients after resection or OLTX remains un[r]

identification of several low-molecular-weight compounds that bind to the hydrophobic pockets of either Bcl-2 or Bcl-XL and block their ability to associate with death-inducing BH3-only proteins. These compounds inhibit the antiapoptotic activities of Bcl-2 and Bcl-XL at nanomol[r]

Gupta S, Wistuba II: Decitabine effect on tumor global DNA methylationand other parameters in a phase I trial in refractory solid tumors andlymphomas. Clin Cancer Res 2009, 15(11):3881-3888.46. Melenhorst JJ, Scheinberg P, Chattopadhyay PK, Gostick E, Ladell K,Roederer M, Hensel NF, Douek DC, Barret[r]

Few reports have described clinical features, prognosis and prognostic factors of osteosarcoma patients according to age. Analysis of this cohort of osteosarcoma patients revealed some unique clinical, therapeutic and prognostic features according to age groups in the largest cohort.

Chapter 081. Principles of Cancer Treatment (Part 19) Solid Tumors Small-molecule epidermal growth factor (EGF) antagonists act at the ATP binding site of the EGF receptor tyrosine kinase. In early clinical trials, gefitinib showed evidence of responses in a small[r]

DIABETES Diabetes and Sirolimus-Eluting Stent Trial, E-SIRIUS European Multicenter, Randomized, Double-Blind Study of the Sirolimus-Coated Bx Velocity Balloon-Expandable Stent in the Treatment of Patients with De Novo Coronary Artery Lesions (NCT00235144), PRISON II Primary Stenting